SCHEMBL997656

SCHEMBL997656

O=S(=O)(O)COc1cccnn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.33
CCR2 P41597 1/20 0.33
CYP1A2 P05177 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ALOX12 P18054 1/20 0.32
NAPRT Q6XQN6 1/20 0.32
PER2 O15055 1/20 0.32
CRY1 Q16526 1/20 0.32
CRY2 Q49AN0 1/20 0.32
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HDAC5 Q9UQL6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28443035 0.98 P2RX7 (0.35) P2RX7CTDSP1CCR2CYP1A2KDM4E
SCHEMBL129825 0.83 P2RX7 (0.34) P2RX7CTDSP1CCR2CYP1A2KDM4E
SCHEMBL31067927 0.76 P2RX7 (0.35) P2RX7CTDSP1CCR2CYP1A2KDM4E
SCHEMBL361395 0.73 KMT2A (0.47) P2RX7CYP1A2ALDH1A1MAPTHTT
SCHEMBL9255278 0.72 CYP1A2 (0.46) P2RX7CTDSP1CYP1A2KDM4EALOX12
SCHEMBL30225243 0.72 ALDH1A1 (0.42) P2RX7CTDSP1CYP1A2ALDH1A1L3MBTL1
SCHEMBL30226513 0.72 ALDH1A1 (0.42) P2RX7CTDSP1CYP1A2ALDH1A1L3MBTL1
SCHEMBL7058599 0.71 CYP1A2 (0.33) P2RX7CTDSP1CCR2CYP1A2NAPRT
SCHEMBL31092422 0.71
SCHEMBL31151688 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239822-A1 CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS FLEURIR ABX LLC (US) 2023-12-14 WO claimed
EP-1899404-B1 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO LTD (KR) 2020-11-04 EP claimed
CN-106124659-A The method of prediction sulfa antibiotics rate of photocatalytic oxidation 井冈山大学 2016-11-16 CN claimed
EP-2150568-B1 CHAIN-END FUNCTIONALIZED METHOXY POLY(ETHYLENE GLYCOL)AND METAL NANO-PARTICLES USING THE SAME YOUL CHON CHEMICAL CO LTD (KR) 2016-03-23 EP claimed
US-9005583-B2 Chain-end functionalized poly(ethykene oxide) and process for the preparation of a nano-sized transition metal or metal salt using the same YOUL CHON CHEMICAL CO., LTD. (KR) 2015-04-14 US claimed
JP-2010528172-A 2010-08-19 JP claimed
US-20100172996-A1 Chain-End Functionalized Methoxy Poly(Ethylene Glycol) and Metal Nano-Particles Using the Same YOUL CHON CHEMICAL CO., LTD. (KR) 2010-07-08 US claimed
EP-2150568-A1 CHAIN-END FUNCTIONALIZED METHOXY POLY(ETHYLENE GLYCOL)AND METAL NANO-PARTICLES USING THE SAME Youl Chon Chemical Co. Ltd. (KR) 2010-02-10 EP claimed
EP-1899404-A4 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO LTD (KR) 2009-09-09 EP claimed
US-20090142268-A1 CHAIN-END FUNCTIONALIZED POLY(ETHYKENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO., LTD. (KR) 2009-06-04 US claimed
JP-2009500488-A 2009-01-08 JP claimed
WO-2008147128-A1 CHAIN-END FUNCTIONALIZED METHOXY POLY(ETHYLENE GLYCOL)AND METAL NANO-PARTICLES USING THE SAME YOUL CHON CHEMICAL CO., LTD. (KR) 2008-12-04 WO claimed
EP-1899404-A1 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME Youl Chon Chemical Co. Ltd. (KR) 2008-03-19 EP claimed
WO-2007007976-A1 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO., LTD. (KR) 2007-01-18 WO claimed
US-20070009592-A1 IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM UNIVERSITEIT GENT (BE) 2007-01-11 US claimed
EP-0255100-A2 Use of trimetrexate and its salts for the preparation of pharmaceutical compositions for treating infections of the mycobacterium-avium-intracellulare complex WARNER-LAMBERT COMPANY (US) 1988-02-03 EP claimed
US-4661340-A Quail egg based stabilized foam compositions for cosmetic purposes INTERKEMIA VEGYIPARI GAZDASAGI TARSASAG (HU) 1987-04-28 US claimed
US-4532245-A Pharmaceutical compositions HOFFMANN-LA ROCHE INC. (US) 1985-07-30 US claimed
US-4082842-A SULFONYLUREA-TYPE HYPOGLYCEMIC, ASCORBIC ACID, SULFAMETHOXYPYRIDAZINE NAHLE ARMANDO 1978-04-04 US claimed
EP-3220920-B1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS FLEURIR ABX LLC (US) 2025-06-04 EP disclosed
CN-120022878-A Amphiphilic covalent organic framework mixed mode chromatographic stationary phase and preparation method and application thereof 河南工业大学 2025-05-23 CN disclosed
EP-4536217-A1 CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS Fleurir Abx LLC (US) 2025-04-16 EP disclosed
CN-118750586-A Collagen-based pharmaceutical compositions and devices and methods of manufacture and use thereof 莎思坦控股有限责任公司 2024-10-11 CN disclosed
CN-118750585-A Collagen-based pharmaceutical compositions and devices and methods of manufacture and use thereof 莎思坦控股有限责任公司 2024-10-11 CN disclosed
CN-118717953-A Collagen-based pharmaceutical compositions and devices and methods of manufacture and use thereof 莎思坦控股有限责任公司 2024-10-01 CN disclosed
US-20240293434-A1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS FLEURIR ABX LLC (US) 2024-09-05 US disclosed
US-11925653-B2 Combination therapy effective against microorganisms, including drug resistant microorganisms FLEURIR ABX, LLC (US) 2024-03-12 US disclosed
CN-117330743-A Method for rapidly detecting toxicity of mixture of microplastic and antibiotic by using scenedesmus obliquus 桂林理工大学 2024-01-02 CN disclosed
WO-2023239822-A1 CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS FLEURIR ABX LLC (US) 2023-12-14 WO disclosed
US-20230398101-A1 Co-agents as Therapy Against Anaerobic Pathogens FLEURIR ABX LLC (US) 2023-12-14 US disclosed
CN-117092266-A Method for detecting sulfonamide veterinary drug residue mixed solution sample in methanol 青岛博栋检测服务有限公司 2023-11-21 CN disclosed
CN-116200393-A Mixed broad-spectrum nucleic acid aptamer for simultaneously detecting 9 sulfonamide drugs 福州大学 2023-06-02 CN disclosed
CN-111848834-B Application of cationic polymer modified by fluorine-containing compound in preparing medicine for transmucosal administration 苏州大学 2023-01-24 CN disclosed
US-20220233557-A1 Combination Therapy Effective Against Microorganisms, Including Drug Resistant Microorganisms FLEURIR ABX LLC (US) 2022-07-28 US disclosed
CN-111604030-B Graphene oxide-covalent organic framework material composite material, capillary electrochromatography column and preparation method 首都师范大学 2022-03-22 CN disclosed
CN-110618224-B [ H ]2Nmim][NTf2]@ UiO-66-Br nano composite material and application thereof 华东师范大学 2021-11-19 CN disclosed
US-10898501-B2 Combination therapy effective against microorganisms, including drug resistant microorganisms FLEURIR ABX, LLC (US) 2021-01-26 US disclosed
CN-112051345-A High performance liquid chromatography detection method for sulfonamides in raw fresh milk 河南省奶牛生产性能测定有限公司 2020-12-08 CN disclosed
EP-1899404-B1 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO LTD (KR) 2020-11-04 EP disclosed
CN-111848834-A Application of cationic polymer modified by fluorine-containing compound in preparing transmucosal drug delivery of drug 苏州大学 2020-10-30 CN disclosed
CN-111848832-A Application of fluorine-containing compound modified cationic polymer as drug carrier and preparation method thereof 苏州大学 2020-10-30 CN disclosed
CN-111604030-A Graphene oxide-covalent organic framework material composite material, capillary electrochromatography column and preparation method 首都师范大学 2020-09-01 CN disclosed
CN-110618224-A [ H ]2Nmim][NTf2]@ UiO-66-Br nano composite material and application thereof 华东师范大学 2019-12-27 CN disclosed
CN-110179806-A Sulfa drugs application in preparation of anti-tumor drugs 首都医科大学 2019-08-30 CN disclosed
US-20180369259-A1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS FLEURIR ABX LLC (US) 2018-12-27 US disclosed
CN-108490088-A A kind of detection method of the animal derived product residue of veterinary drug of detection 汕头出入境检验检疫局检验检疫技术中心 2018-09-04 CN disclosed
EP-3220920-A1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS Fleurir Abx LLC (US) 2017-09-27 EP disclosed
CN-106124659-A The method of prediction sulfa antibiotics rate of photocatalytic oxidation 井冈山大学 2016-11-16 CN disclosed
WO-2016081592-A1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS FLEURIR ABX LLC (US) 2016-05-26 WO disclosed
EP-2150568-B1 CHAIN-END FUNCTIONALIZED METHOXY POLY(ETHYLENE GLYCOL)AND METAL NANO-PARTICLES USING THE SAME YOUL CHON CHEMICAL CO LTD (KR) 2016-03-23 EP disclosed
CN-104084176-B Rich water chromatographic stationary phases of a kind of silver nano-grain-lactose bonded silica gel and preparation method thereof COMPREHENSIVE INSPECTION AND QUARANTINE TECHNOLOGY CENTER, ZHENJIANG ENTRY-EXIT INSPECTION AND QUARANTINE BUREAU (CN) 2016-02-17 CN disclosed
CN-104028253-B A kind of gold nano grain-polysaccharide bonded silica gel stationary phase and preparation method thereof COMPREHENSIVE INSPECTION AND QUARANTINE TECHNOLOGY CENTER, ZHENJIANG ENTRY-EXIT INSPECTION AND QUARANTINE BUREAU (CN) 2015-10-28 CN disclosed
US-9005583-B2 Chain-end functionalized poly(ethykene oxide) and process for the preparation of a nano-sized transition metal or metal salt using the same YOUL CHON CHEMICAL CO., LTD. (KR) 2015-04-14 US disclosed
CN-104084176-A Silver nanoparticle-lactose bonded silica gel stationary phase for Per aqueous chromatography, and preparation method thereof INSPECTION AND QUARANTINE COMPREHENSIVE TECHNOLOGY CT OF ZHENJIANG ENTRY EXIT INSPECTION AND QUARANT 2014-10-08 CN disclosed
CN-104028253-A Gold nanoparticle-polysaccharide bonded silica gel fixed phase and preparation method thereof INSPECTION AND QUARANTINE COMPREHENSIVE TECHNOLOGY CT OF ZHENJIANG ENTRY EXIT INSPECTION AND QUARANT 2014-09-10 CN disclosed
US-8349366-B2 Immediate release pharmaceutical granule compositions and a continuous process for making them UNIVERSITEIT GENT (BE) 2013-01-08 US disclosed
US-8337897-B2 Immediate release pharmaceutical granule compositions and a continuous process for making them UNIVERSITEIT GENT (BE) 2012-12-25 US disclosed
US-8258137-B2 Process for release of biologically active species from mesoporous oxide systems KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-09-04 US disclosed
US-20110027377-A1 IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM UNIVERSITEIT GENT (BE) 2011-02-03 US disclosed
US-20110008454-A1 IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM UNIVERSITEIT GENT (BE) 2011-01-13 US disclosed
US-20100172996-A1 Chain-End Functionalized Methoxy Poly(Ethylene Glycol) and Metal Nano-Particles Using the Same YOUL CHON CHEMICAL CO., LTD. (KR) 2010-07-08 US disclosed
EP-2150568-A1 CHAIN-END FUNCTIONALIZED METHOXY POLY(ETHYLENE GLYCOL)AND METAL NANO-PARTICLES USING THE SAME Youl Chon Chemical Co. Ltd. (KR) 2010-02-10 EP disclosed
EP-1899404-A4 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO LTD (KR) 2009-09-09 EP disclosed
US-20090192205-A1 PROCESS FOR RELEASE OF BIOLOGICALLY ACTIVE SPECIES KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) 2009-07-30 US disclosed
US-20090142268-A1 CHAIN-END FUNCTIONALIZED POLY(ETHYKENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO., LTD. (KR) 2009-06-04 US disclosed
WO-2008147128-A1 CHAIN-END FUNCTIONALIZED METHOXY POLY(ETHYLENE GLYCOL)AND METAL NANO-PARTICLES USING THE SAME YOUL CHON CHEMICAL CO., LTD. (KR) 2008-12-04 WO disclosed
EP-1899404-A1 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME Youl Chon Chemical Co. Ltd. (KR) 2008-03-19 EP disclosed
WO-2007007976-A1 A CHAIN-END FUNCTIONALIZED POLY(ETHYLENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME YOUL CHON CHEMICAL CO., LTD. (KR) 2007-01-18 WO disclosed
US-20070009592-A1 IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM UNIVERSITEIT GENT (BE) 2007-01-11 US disclosed
US-20050058705-A1 Immediate release pharmaceutical granule compositions and a continuous process for making them UNIVERSITEIT GENT (BE) 2005-03-17 US disclosed
US-6476063-B2 DEVOID OF CENTRAL NERVOUS SYSTEM EFFECTS; TOPICAL AND SYSTEMIC ADMINISTRATION; ANTIPRURITIC AGEENTS; ANALGESICS 1-ARYLMETHYLCARBONYL-2-PYRROLIDIN-1-YL-PIPERAZINES ADOLOR CORPORATION 2002-11-05 US disclosed
US-6114330-A BACTERICIDES HOFFMANN-LA ROCHE INC. (US) 2000-09-05 US disclosed
US-4888327-A EYE INFECTIONS ALCON LABORATORIES, INC. (US) 1989-12-19 US disclosed
US-4532245-A Pharmaceutical compositions HOFFMANN-LA ROCHE INC. (US) 1985-07-30 US disclosed
US-4332796-A MICROCRYSTALS COATED WITH MIXTURES OF PHOSPHOLIPIDS AND NONIONIC SURFACTANTS LABORATORIOS BAGO S.A. (AR) 1982-06-01 US disclosed
US-4211776-A ANTIEMETICS CHOAY S.A. (FR) 1980-07-08 US disclosed
EP-0000336-A1 N-benzylpyrimidinyl-amidines, process for their preparation and medicines containing them BASF Aktiengesellschaft (DE) 1979-01-24 EP disclosed
US-4132786-A ANTIEMETICS, ANTICONVULSANTS, ANESTHETICS, ANTIBIOTICS MOREAU ROBERT C 1979-01-02 US disclosed
US-4082842-A SULFONYLUREA-TYPE HYPOGLYCEMIC, ASCORBIC ACID, SULFAMETHOXYPYRIDAZINE NAHLE ARMANDO 1978-04-04 US disclosed
US-4082842-A SULFONYLUREA-TYPE HYPOGLYCEMIC, ASCORBIC ACID, SULFAMETHOXYPYRIDAZINE NAHLE ARMANDO 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100172996-A1 Chain-End Functionalized Methoxy Poly(Ethylene Glycol) and Metal Nano-Particles Using the Same MPEG1, MLEC, MSN P2RX7 4864/4885CTDSP1 529/4885CCR2 2747/4885
US-20090142268-A1 CHAIN-END FUNCTIONALIZED POLY(ETHYKENE OXIDE) AND PROCESS FOR THE PREPARATION OF A NANO-SIZED TRANSITION METAL OR METAL SALT USING THE SAME SIK1, PROC, POLK P2RX7 4812/4885CTDSP1 410/4885CCR2 3610/4885
US-20240293434-A1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS SLC11A2, MYD88, FPR2 P2RX7 1286/4885CTDSP1 4345/4885CCR2 273/4885
US-11925653-B2 Combination therapy effective against microorganisms, including drug resistant microorganisms SLC11A2, ABCC1, DDT P2RX7 1099/4885CTDSP1 4695/4885CCR2 225/4885
US-20220233557-A1 Combination Therapy Effective Against Microorganisms, Including Drug Resistant Microorganisms SLC11A2, ABCC1, DDT P2RX7 1099/4885CTDSP1 4695/4885CCR2 225/4885
US-20180369259-A1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS SLC11A2, ABCC1, DDT P2RX7 1099/4885CTDSP1 4695/4885CCR2 225/4885
US-10898501-B2 Combination therapy effective against microorganisms, including drug resistant microorganisms SLC11A2, ABCC1, DDT P2RX7 1099/4885CTDSP1 4695/4885CCR2 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.